The $1.9 Billion Pill That's Reshaping Rare Disease M&A
Chiesi Group, a privately held Italian pharma company, is dropping $1.9 billion to buy KalVista and its first-of-its-kind oral pill for hereditary angioedema attacks. The deal tells a bigger story about what rare disease assets are really worth.
A Family Business Goes Shopping
For most of its history, Chiesi Group has been the kind of pharma company you've never heard of. Privately held, family-owned, headquartered in Parma, Italy (yes, like the cheese). It makes solid money in respiratory and specialty care. Not exactly the type to drop $1.9 billion on a single deal.
But that's exactly what just happened. Chiesi agreed to acquire KalVista Pharmaceuticals for $27 per share in cash, its largest transaction ever. The target: a company built around a single pill that treats sudden, painful swelling attacks in people with a rare genetic condition called hereditary angioedema (HAE). The deal is expected to close in Q3 2026, and there's no financing condition; Chiesi already has the money lined up.
This isn't a moonshot bet on an unproven drug. KalVista's pill, EKTERLY (sebetralstat), is already FDA-approved and selling. And that changes the math entirely.
What EKTERLY Actually Does (and Why It Matters)
Hereditary angioedema is a rare genetic disorder that causes sudden, severe swelling episodes. They can hit the face, gut, hands, or airway. An airway attack can be life-threatening. For decades, treating an active attack meant grabbing an injectable: a shot you either give yourself at home or get at a clinic. Think of it like carrying an EpiPen, except the episodes are unpredictable and the injections are more complex.
EKTERLY flipped the script. It's the first and only oral, on-demand treatment for acute HAE attacks. No needles. No clinic visits. Just a pill.
The phase 3 trial (called KONFIDENT) tested it in 136 patients across 17 countries. Patients who took EKTERLY started feeling relief in about 1.8 hours, compared to nearly 6.7 hours for placebo. Both the 300 mg and 600 mg doses crushed placebo on every key measure, with p-values below 0.01 across the board.
Safety was equally clean. Side effect rates were actually lower than placebo (2.3% for the 300 mg dose vs. 4.8% for placebo). No serious adverse events related to the drug. No one dropped out because of side effects. The worst complaint? Headache.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
